ReviewFrontiers in medicine2019
Immune-Monitoring Disease Activity in Primary Membranous Nephropathy.
Review in Frontiers in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy.Frontiers in pharmacology · 2022Pooled it
- Membranous Nephropathy: Antigenic Landscape and a Novel Pathogenetic Model.International journal of molecular sciences · 2026Review
- Rapid diagnosis of membranous nephropathy based on kidney tissue Raman spectroscopy and deep learning.Scientific reports · 2025Article
- Present and Future of IgA Nephropathy and Membranous Nephropathy Immune Monitoring: Insights from Molecular Studies.International journal of molecular sciences · 2023Review
- Toxic Occupational Exposures and Membranous Nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2022Observational
- A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.Medical science monitor : international medical journal of experimental and clinical research · 2021Review
- Helper T Cells in Idiopathic Membranous Nephropathy.Frontiers in immunology · 2021Review
- Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy.Frontiers in immunology · 2021Review
- A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients.Kidney international reports · 2020Article
- Role of Serum and Urine Biomarkers (PLABiomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary membranous nephropathy (MN) is a glomerular disease mediated by autoreactive antibodies, being the main cause of nephrotic syndrome among adult patients. While the pathogenesis of MN is still controversial, the detection of autoantibodies against two specific glomerular antigens, phospholipase A2 receptor (PLA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.